MedTrace Logo

Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer

NCT05362825 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2022-05-11

No results posted yet for this study

Summary

This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including the response rate, the survival rate and the safety profile.

Conditions

  • Liver Metastasis Colon Cancer
  • Synchronous Neoplasm

Interventions

DRUG

Neo-adjuvant Chemotherapy FOLFOXIRI Regimen

Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.

PROCEDURE

synchronous resection surgery

Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery

Sponsors & Collaborators

  • University of Medicine and Pharmacy at Ho Chi Minh City

    collaborator OTHER

  • Cho Ray Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-18
Primary Completion
2024-12-20
Completion
2025-01-23

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05362825 on ClinicalTrials.gov